Gyre Therapeutics Inc (GYRE)

Over the past six months, Gyre Therapeutics' stock price has experienced fluctuations, with a 12.23% rise in the last month but decreases of 9.52% over six months and 41.48% over the last year. Key events include positive Phase 3 trial results for Hydronidone, completion of patient enrollment for Pirfenidone capsules, raising approximately $20 million through a secondary offering in May 2025 and commencing an underwritten public offering of common stock in August 2025, a leadership change with Dr. Han Ying stepping down as CEO, and analyst coverage initiation by Jefferies Financial Group and H.C. Wainwright with "Buy" recommendations.

There is no specific information available regarding demand seasonality for Gyre Therapeutics, Inc.'s products and services. Demand for its products is typically driven by disease prevalence and treatment needs rather than seasonal patterns.

Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on advancing fibrosis-first therapies for chronic diseases, operating within the Health Technology sector, specifically in Biotechnology and Pharmaceutical Preparations. The company develops and commercializes small-molecule anti-inflammatory and anti-fibrotic drugs, with a focus on organ fibrosis. Its major products include Hydronidone (F351) for liver fibrosis, Pirfenidone capsules (ETUARY®) for lung and kidney fibrosis, Avatrombopag (Contiva) for thrombocytopenia, and Nintedanib (Etorel) for SSc-ILD and PF-ILD. Additionally, Gyre has development programs like F573, F528, and F230, with F230 currently in a Phase 1 clinical trial for Pulmonary Arterial Hypertension (PAH).

Gyre Therapeutics, Inc. is headquartered in San Diego, California, United States. The company has a significant operational presence and pipeline development efforts in the People's Republic of China (PRC) through its indirect controlling interest in Gyre Pharmaceuticals.

Gyre Therapeutics' brand reputation in the past year appears to be mixed, with analysts holding a "Hold" consensus rating based on 5 Wall Street analysts, with 2 "Sell" ratings and 3 "Buy" ratings. Despite a promising portfolio of established therapies, the company remains "relatively unrecognized by many investors".

Gyre Therapeutics, Inc. has a notable ownership structure with significant insider and institutional holdings. As of October 8, 2025, the company has 132 institutional owners and shareholders holding a total of 4,067,793 shares. Key institutional investors include Vanguard Group Inc., BlackRock, Inc., and Geode Capital Management, Llc. GNI Group Ltd. is the largest shareholder, owning 72.96% of the company. Insiders hold a substantial 87.16% of the company. Overall, Gyre Therapeutics is owned by 3.54% institutional shareholders and 168.97% Gyre Therapeutics insiders.